PUBLISHER: GlobalData | PRODUCT CODE: 1395949
PUBLISHER: GlobalData | PRODUCT CODE: 1395949
Human Papilloma Virus Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
The model discusses in detail the impact of COVID-19 on Human Papilloma Virus Tests market for the year 2020 and beyond. Human papillomavirus (HPV) is known as the most common sexually transmitted infection (STI) in the world. Human Papillomavirus (HPV) Tests are primarily used to screen for cervical cancer and/or identify women who may be at increased risk of cervical cancer. There are over 150 types of HPV including both high-risk HPV and low-risk HPV. Out of these strains, types HPV-16 and HPV-18 are most commonly associated with development of cervical cancer.
The predominant devices used for HPV detection are Nucleic-acid amplification (NAAT) tests, owing to their high specificity and sensitivity as well as their ability to be adapted for high-throughput testing. Several other HPV DNA detection methods have also been described including in situ hybridization tests, Enzyme Immunoassay (EIA) or enzyme-linked immunosorbent assay (ELISA) kits, and next generation sequencing assays. Factors like favorable government policies, high occurrence rate of HPV infections, and growing cervical cancer screening awareness plans are expected to drive the overall HPV testing market during the forecast period. Genital warts are often caused by non-oncogenic strains of HPV, such as HPV-6 and HPV-11.
The HPV tests includes Human Papilloma Virus (HPV) Nucleic Acid Amplification Tests (NAATs) and Other Human Papilloma Virus (HPV) Test Kits.
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed Human Papilloma Virus Tests and evolving competitive landscape:
Global, Regional and Country level market specific insights:
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Hologic Inc, Qiagen NV, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Biocare Medical LLC, Enzo Biochem Inc, Danaher Corp, Thermo Fisher Scientific Inc and Others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:
The model will enable you to: